These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration. Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249 [TBL] [Abstract][Full Text] [Related]
3. Monitoring and assessing vaccine safety: a European perspective. Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548 [TBL] [Abstract][Full Text] [Related]
4. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe. Bonhoeffer J; Black S; Izurieta H; Zuber P; Sturkenboom M Biologicals; 2012 Sep; 40(5):393-7. PubMed ID: 22902972 [TBL] [Abstract][Full Text] [Related]
5. Vaccines in the pipeline: the path from development to use in the United States. Pickering LK; Walton LR Pediatr Ann; 2013 Aug; 42(8):146-52. PubMed ID: 23910027 [TBL] [Abstract][Full Text] [Related]
6. Assuring the quality, safety, and efficacy of DNA vaccines. Robertson JS; Griffiths E Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466 [TBL] [Abstract][Full Text] [Related]
7. [From molecule to medicine--drug development]. Bruhn C Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355 [No Abstract] [Full Text] [Related]
8. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies. Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248 [TBL] [Abstract][Full Text] [Related]
9. Food and Drug Administration regulation and evaluation of vaccines. Marshall V; Baylor NW Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242 [TBL] [Abstract][Full Text] [Related]
10. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks]. Pfleiderer M; Wichmann O Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841 [TBL] [Abstract][Full Text] [Related]
11. Immunizations in the United States: success, structure, and stress. Orenstein WA; Douglas RG; Rodewald LE; Hinman AR Health Aff (Millwood); 2005; 24(3):599-610. PubMed ID: 15886150 [TBL] [Abstract][Full Text] [Related]
12. [Dengue fever: from disease to vaccination]. Teyssou R Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380 [TBL] [Abstract][Full Text] [Related]
16. Field evaluation of vaccine safety. Tozzi AE Vaccine; 2004 May; 22(15-16):2091-5. PubMed ID: 15121330 [TBL] [Abstract][Full Text] [Related]
17. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007. Gruber MF Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396 [TBL] [Abstract][Full Text] [Related]
18. Development and approval of vaccines in the United States. Botstein P Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047 [TBL] [Abstract][Full Text] [Related]